natgillin/translations-raw huggingface dataset:
Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems).
osip, crvenilo kože s mjehurićima na usnama, očima, koži ili u ustima, ljuštenje kože, vrućica, izdignute crvene ili ljubičastemrljena koži, svrbež, osjećaj žarenja, pojava gnojnih mjehurića (znakovi kožnih problema).
Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems).
osip, crvenilo kože s mjehurićima na usnama, očima, koži ili u ustima, ljuštenje kože, vrućica, izdignuti crveni ili ljubičasti plikovi na koži, svrbež, osjećaj žarenja, pojava gnojnih mjehurića (znakovi kožnih problema)
Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems).
Osip, crvenilo kože s mjehurićima na usnama, očima, koži ili u ustima, ljuštenje kože, vrućica, izdignuti crveni ili ljubičasti plikovi na koži, svrbež, osjećaj žarenja, pojava gnojnih mjehurića (znakovi kožnih problema).
rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever
osip, crvena koža, stvaranje mjehurića na usnicama, očima ili ustima, ljuštenje kože, vrućica
Rash, reddened skin
osip, crvenilo kože
rash, redness of the skin in the face, joint pain, fever, weakness and others caused by the medicine (drug-induced lupus erythematosus), frequency unknown severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs (pulmonary arterial hypertension), frequency unknown.
osip, crvenilo kože lica, bol u zglobovima, vrućica, slabost i ostale nuspojave uzrokovane lijekom (lupus eritematosus uzrokovan lijekom), učestalost nepoznata jako suženje krvnih žila u plućima što rezultira visokim krvnim tlakom u krvnim žilama koje prenose krv iz srca u pluća (plućna arterijska hipertenzija).
rash, redness of the skin in the face, joint pain, fever, weakness and others caused by the medicine (drug-induced lupus erythematosus), frequency unknown. severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs (pulmonary arterial hypertension), (frequency unknown).
osip, crvenilo kože lica, bol u zglobovima, vrućica, slabost i ostalo uzrokovano lijekom (lupus eritematosus uzrokovan lijekom), nepoznata učestalost. jako suženje krvnih žila u plućima što rezultira visokim krvnim tlakom u krvnim žilama koje prenose krv iz srca u pluća (plućna arterijska hipertenzija), (nepoznata učestalost).
rash, redness of the skin,
osip, crvenilo kože,
Rash, scaling, irritation, redness
osip, ljuskice, nadraženost, crvenilo
rash, skin allergy, urticaria (pinkish, itchy swellings on the skin); fatigue (tiredness).
osip, alergije kože, urtikarija (ružičaste otekline na koži s svrbeži); umor.
rash, skin allergy, urticaria (pinkish, itchy swellings on the skin); fatigue (tiredness).
osip, alergije kože, urtikarija (ružičaste otekline na koži sa svrbeži); umor.
rash, skin condition with itching, redness and/or dryness (eczema).
osip, promjene na koži sa svrbežom, crvenilom i/ili suhoćom (ekcem).
Rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.
Osip, poteškoće gutanja ili disanja, oticanje usana, lica, grla ili jezika.
rash, sweating increased, contusion alopecia angioneurotic oedema, pruritus, rash vesicular, urticaria, aggravation of psoriasis
osip, pojačano znojenje, kontuzija alopecija angioneurotski edem, pruritis, vezikularni osip, urtikarija, pogoršanje psorijaze
rash, swelling of your lips, mouth, tongue or throat with difficulty breathing (hypersensitivity),
osip, oticanje usana, usta, jezika ili grla uz oteţano disanje (preosjetljivost),
Rash, Urticaria
osip, urtikarija
Rash, Urticaria,
Svi stupnjevi
Rash, Urticaria,
urtikarija, fotosenzibilna
rash, urticaria, pruritus
osip, urtikarija, pruritus
Rash, urticaria, pruritus
osip, urtikarija, svrbež
Rash, urticaria, pruritus1.
Osip, urtikarija, pruritus1
rash, which may be itchy and include swelling, blistering or red patches on the skin.
osip koji može svrbjeti i uključivati oticanje, stvaranje mjehura ili crvenih mrlja na koži
Rash.
osip
Rash.
osip.
Rash.
osip;
Rash.
vrbež. osip.
Rash/ desquamation
osip/ deskvamacija
Rash/ desquamation
osip/deskvamacija
Rash/desquamation
osip/ deskvamacija
Rash/desquamation
osip/deskvamacija
Rash/erythema
Osip/eritem
rash/hives developing antibodies to VPRIV (see section 2)
osip/koprivnjača razvijanje protutijela na VPRIV (vidjeti dio 2)
rash/itchy rash local reactions where you injected the medication (e.g. burning sensation, temporary redness)
osip/osip praćen svrbežom lokalne reakcije na mjestu injiciranja lijeka (npr. osjećaj peckanja, privremeno crvenilo)
rash1, 2, 3
osip1, 2, 3
rash1, 3
osip1,3
Rash2
Osip2
Rash3
Osip3
Rash3 Pruritus3
Osip3 Pruritus3
Rash5
osip5
rash;
osip;
rash; abnormal blood test results (increased levels of certain liver enzymes).
osip; poremećeni nalaz krvnih pretraga (povećane razine određenih jetrenih enzima).
Rash; Acne
osip, akne
rash; asthenia/fatigue (tiredness).
osip; astenija /umor (zamaranje).
rash; asthenia/fatigue (tiredness).
osip; astenija/umor (zamaranje).
Rash; Dry skin; Pruritus
osip; suha koža; svrbež
rash; itching (pruritus)
osip, svrbež (pruritus)
rash; musculoskeletal pain.
osip, mišićno-koštana bol.
rash; redness of the skin,
osip, crvenilo kože,
Rash^; Pruritus
osip^; pruritus
Rasha Alopeciaa
Glavobolja
Rasha Alopeciaa
Osipa Alopecijaa
Rasha Alopeciaa
Osipa, alopecijaa
RashC
osipC
rashc, pruritusc
osipc, svrbežc
Rashc, Urticaria
Osipc, urtikarija
rashd, pruritus
osipd, svrbež
Rashe
Osipe
rashes
osip
Rashes (including generalised, macular, maculo-papular) Pruritus
osip (uključujući generalizirani, makularni, makulopapularni) pruritus
rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions feeling weak
osipi (uključujući crvene točkice ili mrlje, katkada s pojavom mjehurića i oticanjem kože), koji mogu biti alergijske reakcije osjećaj slabosti
rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
osipi (uključujući crvene točkice ili mrlje, katkada s pojavom mjehurića i oticanjem kože), koji mogu biti alergijske reakcije, svrbež, promjene boje kože, uključujući tamnjenje dijelova kože
rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches other allergic reactions, such as wheezing, swelling or feeling light-headed
osipi (uključujući crvene točkice ili mrlje, katkada s pojavom mjehurića i oticanjem kože), koji mogu biti alergijske reakcije, svrbež, promjene boje kože, uključujući tamnjenje dijelova kože druge alergijske reakcije, kao što su piskanje pri disanju, oticanje ili osjećaj omaglice
rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches pain
osipi (uključujući crvene točkice ili mrlje, katkada s pojavom mjehurića i oticanjem kože), koji mogu biti alergijske reakcije, svrbež, promjene boje kože, uključujući tamnjenje dijelova kože bol
rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches, other allergic reactions, such as wheezing, swelling or feeling light-headed.
osipi (uključujući crvene točkice ili mrlje, katkad s pojavom mjehurića i oticanjem kože), koji mogu biti alergijske reakcije, svrbež, promjene boje kože, uključujući tamnjenje dijelova kože druge alergijske reakcije, kao što su piskanje pri disanju, oticanje ili ošamućenost
Rashes are usually mild -to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with REYATAZ.
Osipi su obično blage do umjerene makulopapularne erupcije koje nastaju tijekom prva 3 tjedna od početka terapije lijekom REYATAZ.
Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities.
Osipi su obično blage do umjerene makulopapulamo eritematozno izbijanje kožnih promjena, s ili bez svrbeža, na trupu, licu i ekstremitetima.
Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities.
Osipi su obično blagi do umjereni makulopapulozno eritematozno izbijanje kožnih promjena, s ili bez svrbeža, na trupu, licu i ekstremitetima.
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with REYATAZ.
Osipi su obično blage do umjereno teške makulopapularne kožne erupcije koje nastaju unutar 3 tjedna od početka terapije lijekom REYATAZ.
Rashes occur alone or in the context of drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lympadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Osip se pojavljuje samostalno ili u sklopu reakcije na lijek uz eozinofiliju i sistemske simptome obilježene osipom i općim simptomima, poput, vrućice, artralgije, mijalgije i limpadenopatije, te visceralne bolesti, poput hepatitisa, eozinofilije, granulocitopenije i disfunkcije bubrega.
Rashes occur alone or in the context of drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lympadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Osip se pojavljuje samostalno ili u sklopu reakcije na lijek uz eozinofiliju i sistemske simptome obilježene osipom i općim simptomima, poput, vrućice, artralgije, mijalgije i limpadenopatije, te visceralne poremećaje, poput hepatitisa, eozinofilije, granulocitopenije i disfunkcije bubrega.
Rashes occur alone or in the context of drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lympadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Osip se pojavljuje samostalno ili u sklopu reakcije na lijek uz eozinofiliju i sistemske simptome, poput, vrućice, artralgije, mijalgije i limpadenopatije, te visceralne poremećaje, poput hepatitisa, eozinofilije, granulocitopenije i disfunkcije bubrega.
rashes that may be itchy or blistering
osip sa svrbežom ili pojavom mjehurića
rashes which may be itchy or inflamed (flat or raised spots or blisters)
osip koji može svrbjeti ili biti upaljen (ravne ili izdignute mrlje ili mjehuri)
Rashes, itching and rapid swelling of the tissues of the neck, face, mouth or throat
osip, svrbež i naglo oticanje tkiva vrata, lica, usta ili grla
Rashes, itching, abnormal touch sensation
Osip, svrbež, poremećaj osjeta dodira
rashes, itching, red patches on the skin
osipi, svrbež, crvene mrlje po koži
rashes, itching, red patches on the skin.
osipi, svrbež, crvene mrlje po koži
Rashes, skin rash, itching, hives or reactions to sunlight or exposure to UV light (photosensitivity reactions), scalp/hair abnormality (including hair loss)
Osipi, kožni osip, svrbež, koprivnjača ili reakcije na sunčevu svjetlost ili na izlaganje UV svjetlu (fotosenzitivne reakcije), poremećaji vlasišta/kose (uključujući gubitak kose)
Rashes.
osipi
Rashes; abnormal results in liver function test.
Osipi; abnormalni rezultati pretraga jetrene funkcije.
Rashh
Osiph
Rashi
Osipi
rashk, pruritusl
osipk, pruritusl
Rashk; urticaria
osipk; urtikarija
Rash†
osip
Rasilamlo 150 mg/10 mg film-coated tablets Aliskiren/amlodipine
Rasilamlo 150 mg/10 mg filmom obložene tablete aliskiren/amlodipin
Rasilamlo 150 mg/10 mg tablets Aliskiren/amlodipine
Rasilamlo 150 mg/10 mg tablete aliskiren/amlodipin
Rasilamlo 150 mg/5 mg film-coated tablets Aliskiren/amlodipine
Rasilamlo 150 mg/5 mg filmom obložene tablete aliskiren/amlodipin
Rasilamlo 150 mg/5 mg film-coated tablets are light yellow, convex, oval film-coated tablets, with “T2” debossed on one side and “NVR” on the other.
Rasilamlo 150 mg/5 mg filmom obložene tablete su svijetlo žute, konveksne, ovalne filmom obložene tablete, s utisnutom oznakom „T2“ na jednoj i „NVR“ na drugoj strani.
Rasilamlo 150 mg/5 mg tablets Aliskiren/amlodipine
Rasilamlo 150 mg/5 mg tablete aliskiren/amlodipin
Rasilamlo 300 mg/10 mg film-coated tablets Aliskiren/amlodipine
Rasilamlo 300 mg/10 mg filmom obložene tablete aliskiren/amlodipin
Rasilamlo 300 mg/10 mg tablets Aliskiren/amlodipine
Rasilamlo 300 mg/10 mg tablete aliskiren/amlodipin
Rasilamlo 300 mg/5 mg film-coated tablets Aliskiren/amlodipine
Rasilamlo 300 mg/5 mg filmom obložene tablete aliskiren/amlodipin
Rasilamlo 300 mg/5 mg tablets Aliskiren/amlodipine
Rasilamlo 300 mg/5 mg tablete aliskiren/amlodipin
Rasilamlo can be used with other antihypertensive medicines, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors’ or ‘angiotensin receptor blockers’ (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Rasilamlo se može koristiti zajedno s drugim antihipertenzicima, uz iznimku „inhibitora angiotenzin konvertirajućeg enzima (ACE)” ili „blokatora receptora angiotenzina” (ARB-ova) u bolesnika sa šećernom bolešću ili umjerenim do ozbiljnim oštećenjem bubrežne funkcije.
Rasilamlo is for use in adults.
Rasilamlo je namijenjen primjeni u odraslih.
Rasilamlo is not recommended in patients with severe renal impairment (GFR <30 ml/min/1.73 m2).
Rasilamlo se ne preporučuje bolesnicima s teškim oštećenjem bubrežne funkcije (GFR <30 ml/min/1,73 m2).
Rasilamlo is not recommended in patients with severe renal impairment (GFR <30 ml/min/1.73 m2).
Rasilamlo se ne preporučuje u bolesnika s teškim oštećenjem bubrežne funkcije (GFR <30 ml/min/1,73 m2).
Rasilamlo is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone. 'Essential' means that the hypertension has no obvious cause.
Rasilamlo se koristi za liječenje esencijalne hipertenzije (visokog krvnog tlaka) u odraslih osoba čiji krvni tlak nije odgovarajuće kontroliran monoterapijom aliskirena ili amlodipina.
Rasilamlo may be administered with other antihypertensive medicinal products with the exception of use in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.1).
Rasilamlo se može primjenjivati s drugim antihipertenzivnim lijekovima izuzimajući primjenu u kombinaciji s inhibitorima angiotenzin konvertirajućeg enzima (ACEI) ili blokatorima receptora angiotenzina II (ARB) u bolesnika sa šećernom bolešću ili oštećenjem bubrežne funkcije (brzina glomerularne filtracije (GFR) <60 ml/min/1,73 m2) (vidjeti dijelove 4.3, 4.4 i 5.1).
Rasilez 150 mg film-coated tablets Aliskiren
Rasilez 150 mg filmom obložene tablete aliskiren
Rasilez 150 mg film-coated tablets are available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.
Rasilez 150 mg filmom obložene tablete su dostupne u pakiranjima od 7, 14, 28, 30, 50, 56, 84, 90, 98 ili 280 tableta.
Rasilez 150 mg film-coated tablets are light-pink, biconvex round tablets, imprinted “IL” on one side and “NVR” on the other side.
Rasilez 150 mg filmom obložene tablete su svijetloružičaste, bikonveksne, okrugle tablete, s utisnutom oznakom „IL“ na jednoj i „NVR“ na drugoj strani.
Rasilez 150 mg film-coated tablets contain 150 mg aliskiren and Rasilez 300 mg film-coated tablets contain 300 mg aliskiren.
Rasilez 150 mg filmom obložene tablete sadrže 150 mg aliskirena i Rasilez 300 mg filmom obložene tablete sadrže 300 mg aliskirena.
Rasilez 150 mg film-coated tablets PA/Alu/PVC – Alu blisters:
Rasilez 150 mg filmom obložene tablete PA/Al/PVC – Al blisteri:
Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets Aliskiren
Rasilez 150 mg filmom obložene tablete Rasilez 300 mg filmom obložene tablete aliskiren
Rasilez 300 mg film-coated tablets Aliskiren
Rasilez 300 mg filmom obložene tablete aliskiren
Rasilez 300 mg film-coated tablets are available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.
Rasilez 300 mg filmom obložene tablete su dostupne u pakiranjima od 7, 14, 28, 30, 50, 56, 84, 90, 98 ili 280 tableta.
Rasilez 300 mg film-coated tablets PA/Alu/PVC – Alu blisters:
Rasilez 300 mg filmom obložene tablete PA/Al/PVC – Al blisteri:
Rasilez has been evaluated for safety in more than 7,800 patients, including over 2,300 treated for over 6 months, and more than 1,200 for over 1 year.
Sigurnost Rasileza ispitivana je u više od 7800 bolesnika uključujući više od 2300 bolesnika liječenih duže od 6 mjeseci te više od 1200 bolesnika liječenih duže od 1 godine.
Rasilez has been studied in 1,864 patients aged 65 years or older, and in 426 patients aged 75 years or older.
Rasilez je ispitivan u 1864 bolesnika u dobi od 65 godina ili starijih te u 426 bolesnika u dobi od 75 godina ili starijih.
Rasilez has negligible influence on the ability to drive and use machines.
Rasilez zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Rasilez HCT 150 mg/12.5 mg film-coated tablets Aliskiren/hydrochlorothiazide
Rasilez HCT 150 mg/12,5 mg filmom obložene tablete aliskiren/hidroklorotiazid
Rasilez HCT 150 mg/12.5 mg film-coated tablets are white, oval film-coated tablets imprinted with “LCI” on one side and “NVR” on the other.
Rasilez HCT 150 mg/12,5 mg filmom obložene tablete su bijele, ovalne filmom obložene tablete, s utisnutom oznakom „LCI“ na jednoj i „NVR“ na drugoj strani.
Rasilez HCT 150 mg/12.5 mg film-coated tablets EU/1/08/491/001-020
Rasilez HCT 150 mg/12,5 mg filmom obložene tablete EU/1/08/491/001-020
Rasilez HCT 150 mg/12.5 mg film-coated tablets Tablet core:
Rasilez HCT 150 mg/12,5 mg filmom obložene tablete Jezgra tablete:
Rasilez HCT 150 mg/25 mg film-coated tablets Aliskiren/hydrochlorothiazide
Rasilez HCT 150 mg/25 mg filmom obložene tablete aliskiren/hidroklorotiazid
Rasilez HCT 150 mg/25 mg film-coated tablets Tablet core:
Rasilez HCT 150 mg/25 mg filmom obložene tablete Jezgra tablete:
Rasilez HCT 300 mg/12.5 mg film-coated tablets Aliskiren/hydrochlorothiazide
Rasilez HCT 300 mg/12,5 mg filmom obložene tablete aliskiren/hidroklorotiazid
Rasilez HCT 300 mg/12.5 mg film-coated tablets Tablet core:
Rasilez HCT 300 mg/12,5 mg filmom obložene tablete Jezgra tablete:
Rasilez HCT 300 mg/25 mg film-coated tablets Aliskiren/hydrochlorothiazide
Rasilez HCT 300 mg/25 mg filmom obložene tablete aliskiren/hidroklorotiazid
Rasilez HCT 300 mg/25 mg film-coated tablets Tablet core:
Rasilez HCT 300 mg/25 mg filmom obložene tablete Jezgra tablete:
Rasilez HCT combines two antihypertensive compounds to control blood pressure in patients with essential hypertension: Aliskiren belongs to the class of direct renin inhibitors and hydrochlorothiazide to the class of thiazide diuretics.
Rasilez HCT je kombinacija dvaju antihipertenzivnih lijekova za kontrolu krvnog tlaka u bolesnika s esencijalnom hipertenzijom: aliskiren pripada skupini direktnih inhibitora renina, a hidroklorotiazid skupini tiazidnih diuretika.
Rasilez HCT contains lactose (milk sugar).
Rasilez HCT sadrži laktozu (mliječni šećer).
Rasilez HCT contains lactose and wheat starch
Rasilez HCT sadrži laktozu i pšenični škrob
Rasilez HCT contains two active substances, aliskiren and hydrochlorothiazide.
Rasilez HCT sadrži dvije djelatne tvari, aliskiren i hidroklorotiazid.
Rasilez HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors’ or ‘angiotensin receptor blockers’ (ARBs) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Rasilez HCT u kombinaciji s „inhibitorima enzima koji konvertira angiotenzin (ACE)” ili „blokatorima receptora angiotenzina (ARB)” ne smije se koristiti u bolesnika s dijabetesom, ili umjerenim ili ozbiljnim oštećenjem funkcije bubrega.
Rasilez HCT is a medicine that contains the active substances aliskiren and hydrochlorothiazide.
Rasilez HCT je lijek koji sadrži djelatne tvari aliskiren i hidroklorotiazid.
Rasilez HCT is available in packs containing 7, 14, 28, 30, 50, 56, 90,or 98 tablets.
Rasilez HCT je dostupan u pakiranjima od 7, 14, 28, 30, 50, 56, 90, ili 98 tableta.
Rasilez HCT is contraindicated in children from birth to less than 2 years and should not be used in children aged 2 to less than 6 years because of safety concerns due to potential aliskiren overexposure (see sections 4.3, 4.4, 5.2, and 5.3).
Rasilez HCT je kontraindiciran u djece od rođenja do nenavršene 2 godine i ne bi se smio koristiti u djece u dobi od 2 do nenavršenih 6 godina zbog sigurnosnih problema uzrokovanih potencijalnom prekomjernom izloženošću aliskirenu (vidjeti dijelove 4.3, 4.4, 5.2, i 5.3).
Rasilez HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre- existing hypercalcaemia.
Rasilez HCT je kontraindiciran u bolesnika s hiperkalcijemijom te se može primjenjivati tek nakon ispravka već postojeće hiperkalcemije.
Rasilez HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre- existing hypercalcaemia.
Rasilez HCT je kontraindiciran u bolesnika s hiperkalcijemijom te se smije primjenjivati tek nakon ispravka, već postojeće hiperkalcijemije.
Rasilez HCT is contraindicated in patients with severe hepatic impairment and should be used with caution in patients with mild to moderate hepatic impairment or progressive liver disease.
Rasilez HCT je kontraindiciran u bolesnika s teškim oštećenjem jetrene funkcije, dok se u bolesnika s blagim do umjerenim oštećenjem jetrene funkcije ili progresivnom bolešću jetre mora primjenjivati s oprezom.
Rasilez HCT is contraindicated in patients with severe renal impairment or anuria (see section 4.3).
Rasilez HCT je kontraindiciran u bolesnika s teškim oštećenjem bubrežne funkcije ili anurijom (vidjeti dio 4.3).
Rasilez HCT is for use in adults only; it must not be used in children aged less than 2 years and is not recommended for older children.
Rasilez HCT se primjenjuje samo u odraslih; ne smije se primjenjivati u djece mlađe od dvije godine, a ne preporučuje se ni u starije djece.
Rasilez HCT is for use in adults.
Rasilez HCT je namijenjen primjeni u odraslih.
Rasilez HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.
Rasilez HCT je indiciran kao zamjenska terapija u bolesnika odgovarajuće kontroliranih istodobnom primjenom aliskirena i hidroklorotiazida u istim dozama kao u kombinaciji.
Rasilez HCT is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Rasilez HCT se ne preporučuje za vrijeme trudnoće te se ne smije uzimati ako ste trudni više od 3 mjeseca, jer može ozbiljno naštetiti Vašem djetetu ako se koristi nakon trećeg mjeseca trudnoće.
Rasilez HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.
Rasilez HCT se ne preporučuje majkama koje doje, a ako želite dojiti liječnik Vam može odabrati drugo liječenje.